The Wistar Institute’s David B. Weiner, Ph.D., and his laboratory created a new therapeutic design for glioblastoma, the deadliest form of brain cancer. The lab engineered molecules called trispecifics that connect cancer-killing T cells with not just one but two different brain cancer receptors.
